Surgical Staging for the Treatment of Endometrial Cancer Based on IOC
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 401
- 试验地点
- 2
- 主要终点
- Recurrence-free survival
研究概览
简要总结
Complete pelvic and para-aortic lymphadenectomy performed at the time of primary surgical staging for endometrial cancer increases operative time and surgical morbidity, but appears to be necessary in most high grade and deeply invasive cancers. To date, the Mayo Clinic approach has not been reproduced, and the investigators propose to validate their algorithm at the University of Kentucky utilizing intra-operative consultation (IOC). The preliminary data at the University of Kentucky for IOC and endometrial cancer outcomes suggest that the investigators are well-suited to perform this investigation. A surgical approach that is tailored to the patient's cancer biology is rational, supported by the recent literature, and medically compelling since the co-morbidities of many obese, low-risk EC patients put them at significantly increased perioperative risk for complete lymphadenectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •All patients must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy.
- •Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation.
- •Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound. Preoperative imaging is not mandatory for study enrollment.
- •Patients may have received prior systemic chemotherapy. Such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy. Patients must not have received neoadjuvant chemotherapy for the present disease.
- •Patients must have GOG performance status 0, 1, or
- •Patients must have an estimated survival greater than or equal to 3 months
- •Patients must have signed an approved informed consent and HIPAA authorization.
排除标准
- •Patients with clinical evidence of disease beyond the uterus, including presence of suspicious aortic or inguinal nodes on imaging or clinical exam.
- •Patients who have received previous vaginal, pelvic, or abdominal irradiation.
- •Patients who received chemotherapy directed at the present disease.
- •Patients who have circumstances that will not permit completion of this study or the required follow-up.
- •Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of surgical lymph node assessments.
- •Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years.
- •Patients with GOG Performance Grade of 3 or 4.
结局指标
主要结局
Recurrence-free survival
时间窗: 24 months
Recurrence-free survival rates in low-risk and high-risk subgroups of patients with endometrial cancer as classified by the use of pathology intraoperative consultation (IOC).
次要结局
- Progression-free survival(5 years)
- Disease-specific Survival(5 years)
- Concordance between IOC and final pathology Incidence(5 years)
- Perioperative morbidity and mortality(5 years)
- Overall patient survival(5 years)
研究者
Frederick R. Ueland, M.D.
Professor, Obstetrics and Gynecology
University of Kentucky